Sequenom Announces Amendment to Multi-Year Supply Agreement with Illumina

SAN DIEGO,– Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it has extended the term of a supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools and integrated systems for the large scale-analysis of genetic variation and function.

The amendment extends the term of the supply agreement from three years to five years, terminating in July 2016. Sequenom and its subsidiaries purchase Illumina’s sequencing equipment and consumables for use in the cell-free detection of fetal chromosomal abnormalities in maternal blood.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

< | >